

**OptiBiotix Health plc**  
("OptiBiotix" or the "Company")

**Directorate change**

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease, diabetes and skincare, announces that René Kamminga a Director of the Company and CEO of OptiBiotix Ltd, a wholly owned subsidiary of OptiBiotix Health plc, will leave the business on 28 February 2023 to pursue other opportunities. Stephen O'Hara, CEO of OptiBiotix Health plc will resume the role as CEO of OptiBiotix Ltd and will lead a minor restructuring of the business, with further announcements to be made in due course.

**Stephen O'Hara, CEO of OptiBiotix, commented:** "I would like to thank René for his contribution since his appointment in March 2021 and wish him well in his next move. René has helped develop the OptiBiotix business leading the transition from distributor to more direct selling and broadening the product portfolio with the addition of Opti-XOS and WellBiome®. He has been instrumental in opening up business opportunities in the US, Middle east, and Asia Pacific which we hope will mature into number of key accounts in 2023. René has helped build resilience and greater opportunity within the OptiBiotix portfolio creating the potential for building significant sales and shareholder value as we move through 2023 and beyond."

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

**For further information, please contact:**

**OptiBiotix Health plc**

Neil Davidson, Chairman  
Stephen O'Hara, Chief Executive

[www.optibiotix.com](http://www.optibiotix.com)

Contact via Walbrook below

**Cairn Financial Advisers LLP (NOMAD)**

Liam Murray / Jo Turner / Ludovico Lazzaretti

Tel: 020 7213 0880

**Cenkos Securities plc (Joint Broker)**

Callum Davidson  
Michael Johnson / Russell Kerr (Sales)

Tel: 020 7397 8900

**Peterhouse Capital Limited (Joint Broker)**

Duncan Vasey/ Lucy Williams

Tel: 020 7220 9797

**Walbrook PR Ltd**

Anna Dunphy

Mob: 07876 741 001

**About OptiBiotix - [www.optibiotix.com](http://www.optibiotix.com)**

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than

twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

**Caution regarding forward looking statements**

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as "believe", "could", "should" "envisage", "estimate", "intend", "may", "plan", "potentially", "expect", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAQBFLXLLBBK